Engineering Hafnium Oxide-Based Nanoplatforms for Precision Radiosensitization.

Gao, Mingming; Zhu, Kang; Wang, Zhao; Li, Xiaoyin; Fang, Liping; Chen, Liwei; Mou, Hongyu; Gao, Xing et al. · Adv Healthc Mater · 2026

review · Level V

Where this comes from

Abstract

Hafnium oxide (HfO<sub>2</sub>)-based nanomaterials are emerging as powerful tools to enhance radiotherapy by utilizing their high atomic number (Z). By depositing a greater radiation dose directly within tumors, they offer a promising route to improve treatment efficacy. This review traces the development of HfO<sub>2</sub> nanoradiosensitizers, starting with the clinically established NBTXR3, an approved hafnium-based benchmark for several solid tumors. We analyze the structural characteristics and radiosensitization mechanisms of nanoscale HfO<sub>2</sub>, which include improved X-ray absorption, radical generation, and immunomodulation. Key synthesis methods such as sol-gel, precipitation, and hydrothermal approaches are evaluated in detail, with emphasis on their tunable parameters and reproducibility. Recent progress focuses on material optimization through size control, surface engineering, composite design, and Hf-MOFs, as well as combination strategies. Despite encouraging preclinical results, challenges remain in scalable fabrication, long-term biosafety, and clinical translation. Future directions point toward smart stimuli-responsive platforms and multimodal theranostic systems. This review highlights the potential of HfO<sub>2</sub> to precision radiotherapy while acknowledging existing translational challenges.

Medical subject headings